91 related articles for article (PubMed ID: 18345496)
1. Minimization of potential hERG liability in histamine H3 receptor antagonists.
Black LA; Liu H; Diaz GJ; Fox GB; Browman KE; Wetter J; Marsh KC; Miller TR; Esbenshade TA; Brioni J; Cowart MD
Inflamm Res; 2008; 57 Suppl 1():S45-6. PubMed ID: 18345496
[No Abstract] [Full Text] [Related]
2. Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.
de Lera Ruiz M; Zheng J; Berlin MY; McCormick KD; Aslanian RG; West R; Hwa J; Lachowicz J; van Heek M
Bioorg Med Chem Lett; 2013 Nov; 23(21):6004-9. PubMed ID: 24035485
[TBL] [Abstract][Full Text] [Related]
3. Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity.
Levoin N; Labeeuw O; Calmels T; Poupardin-Olivier O; Berrebi-Bertrand I; Lecomte JM; Schwartz JC; Capet M
Bioorg Med Chem Lett; 2011 Sep; 21(18):5378-83. PubMed ID: 21802950
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships of 2-(1,4'-bipiperidin-1'-yl)thiazolopyridine as H3 receptor antagonists.
Rao AU; Palani A; Chen X; Huang Y; Aslanian RG; West RE; Williams SM; Wu RL; Hwa J; Sondey C; Lachowicz J
Bioorg Med Chem Lett; 2009 Nov; 19(21):6176-80. PubMed ID: 19773164
[TBL] [Abstract][Full Text] [Related]
5. Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.
Labeeuw O; Levoin N; Poupardin-Olivier O; Calmels T; Ligneau X; Berrebi-Bertrand I; Robert P; Lecomte JM; Schwartz JC; Capet M
Bioorg Med Chem Lett; 2011 Sep; 21(18):5384-8. PubMed ID: 21783360
[TBL] [Abstract][Full Text] [Related]
6. Achievement of behavioral efficacy and improved potency in new heterocyclic analogs of benzofuran H3 antagonists.
Cowart M; Faghih R; Gfesser G; Curtis M; Sun M; Zhao C; Bennani Y; Wetter J; Marsh K; Miller TR; Krueger K; Pan JB; Drescher K; Fox GB; Esbenshade TA; Hancock AA
Inflamm Res; 2005 Apr; 54 Suppl 1():S25-6. PubMed ID: 15928820
[No Abstract] [Full Text] [Related]
7. Fluorinated non-imidazole histamine H3 receptor antagonists.
Isensee K; Amon M; Garlapati A; Ligneau X; Camelin JC; Capet M; Schwartz JC; Stark H
Bioorg Med Chem Lett; 2009 Apr; 19(8):2172-5. PubMed ID: 19286376
[TBL] [Abstract][Full Text] [Related]
8. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I).
Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Jun; 23(11):3416-20. PubMed ID: 23591110
[TBL] [Abstract][Full Text] [Related]
9. Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonists.
Nirogi R; Shinde A; Tiriveedhi V; Kota L; Saraf SK; Badange RK; Mohammed AR; Subramanian R; Muddana N; Bhyrapuneni G; Abraham R
Eur J Med Chem; 2016 Jan; 108():655-662. PubMed ID: 26731168
[TBL] [Abstract][Full Text] [Related]
10. Lead optimization of thiazolo[5,4-c]piperidines: 3-cyclobutoxy linker as a key spacer for H(3)R inverse agonists.
Provins L; Denonne F; Célanire S; Christophe B; Defays S; Delaunoy C; Delporte ML; Demaude T; Durieu V; Gillard M; Hubert D; Lamberty Y; Lorent G; Valade A; Vanbellinghen A; Van Houtvin N
ChemMedChem; 2012 Dec; 7(12):2087-92. PubMed ID: 23042668
[TBL] [Abstract][Full Text] [Related]
11. Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists.
Cole DC; Gross JL; Comery TA; Aschmies S; Hirst WD; Kelley C; Kim JI; Kubek K; Ning X; Platt BJ; Robichaud AJ; Solvibile WR; Stock JR; Tawa G; Williams MJ; Ellingboe JW
Bioorg Med Chem Lett; 2010 Feb; 20(3):1237-40. PubMed ID: 20042333
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of a novel series of histamine H3 receptor antagonists through a scaffold hopping strategy.
Gao Z; Hurst WJ; Hall D; Hartung R; Reynolds W; Kang J; Nagorny R; Hendrix JA; George PG
Bioorg Med Chem; 2015 Feb; 23(3):429-38. PubMed ID: 25577710
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.
Zeng Q; Rosenblum SB; Yang Z; Jiang Y; McCormick KD; Aslanian RG; Duguma L; Kozlowski JA; Shih NY; Hey JA; West RE; Korfmacher WA; Berlin M; Boyce CW
Bioorg Med Chem Lett; 2013 Nov; 23(21):6001-3. PubMed ID: 24050887
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.
Tao M; Raddatz R; Aimone LD; Hudkins RL
Bioorg Med Chem Lett; 2011 Oct; 21(20):6126-30. PubMed ID: 21906941
[TBL] [Abstract][Full Text] [Related]
15. Using electrophysiology and in silico three-dimensional modeling to reduce human Ether-à-go-go related gene K(+) channel inhibition in a histamine H3 receptor antagonist program.
Davenport AJ; Möller C; Heifetz A; Mazanetz MP; Law RJ; Ebneth A; Gemkow MJ
Assay Drug Dev Technol; 2010 Dec; 8(6):781-9. PubMed ID: 21133680
[TBL] [Abstract][Full Text] [Related]
16. The discovery of the benzazepine class of histamine H3 receptor antagonists.
Wilson DM; Apps J; Bailey N; Bamford MJ; Beresford IJ; Briggs MA; Calver AR; Crook B; Davis RP; Davis S; Dean DK; Harris L; Heightman TD; Panchal T; Parr CA; Quashie N; Steadman JG; Schogger J; Sehmi SS; Stean TO; Takle AK; Trail BK; White T; Witherington J; Worby A; Medhurst AD
Bioorg Med Chem Lett; 2013 Dec; 23(24):6897-901. PubMed ID: 24161834
[TBL] [Abstract][Full Text] [Related]
17. Novel substituted pyrrolidines are high affinity histamine H3 receptor antagonists.
Stocking EM; Aluisio L; Atack JR; Bonaventure P; Carruthers NI; Dugovic C; Everson A; Fraser I; Jiang X; Leung P; Lord B; Ly KS; Morton KL; Nepomuceno D; Shah CR; Shelton J; Soyode-Johnson A; Letavic MA
Bioorg Med Chem Lett; 2010 May; 20(9):2755-60. PubMed ID: 20382018
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationship (SAR) study of 4-azabenzoxazole analogues as H3 antagonists.
Shao N; Aslanian R; West RE; Williams SM; Wu RL; Hwa J; Sondey C; Lachowicz J; Palani A
Bioorg Med Chem Lett; 2012 Mar; 22(5):2075-8. PubMed ID: 22326166
[TBL] [Abstract][Full Text] [Related]
19. Amine-constrained pyridazinone histamine H₃ receptor antagonists.
Sundar BG; Bailey T; Bacon E; Aimone L; Huang Z; Lyons J; Raddatz R; Hudkins R
Bioorg Med Chem Lett; 2011 Sep; 21(18):5543-6. PubMed ID: 21824776
[TBL] [Abstract][Full Text] [Related]
20. Histamine H3 receptor antagonists ameliorate attention deficit/hyperactivity disorder-like behavioral changes caused by neonatal habenula lesion.
Kim YJ; Goto Y; Lee YA
Behav Pharmacol; 2018 Feb; 29(1):71-78. PubMed ID: 28863002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
